Home >> Tag Archives: Meridian Bioscience—

Tag Archives: Meridian Bioscience—

Learn about molecular testing for M. pneumoniae

Sept. 14, 2016—Donna Mayne, the microbiology, serology, and molecular laboratory manager at Sacred Heart Health System in Pensacola, Fla., outlines the clinical benefits of using molecular technology to detect Mycoplasma pneumoniae in a free program provided by Meridian Bioscience. Watch. In a separate presentation, Vicki Chalker, PhD, head of the respiratory and vaccine-preventable bacteria reference unit of Public Health England’s ...

Read More »

Meridian’s M. pneumonia molecular test cleared

Sept. 2, 2016—Meridian Bioscience has received FDA clearance for a molecular diagnostic test for Mycoplasma pneumonia. The Illumigene Mycoplasma Direct assay, launched earlier this year in Europe, features a simplified three-step procedure. The new procedure is designed to expand Meridian’s customer base by eliminating the need for specialized techniques and training, as well as providing definitive results in less than ...

Read More »

M. pneumoniae molecular test, 7/13:108

Meridian Bioscience has received FDA clearance for its Mycoplasma pneumoniae molecular diagnostic test on the Illumigene platform. By amplifying the specific DNA for the detection of M. pneumoniae, the test provides a definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner.

Read More »

Group A/B strep tests, 4/13:87

Meridian Bioscience’s Illumigene group A Streptococcus and group B Streptococcus tests have been recategorized under CLIA as moderate complexity. The new categorization of these tests allows the Illumigene platform to be available to all moderate-complexity labs in U.S. hospitals and clinics, allowing them to offer an accurate, rapid, simple molecular test for each of these pathogens.

Read More »